Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $118.90 Average Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, twenty have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $118.90.

KYMR has been the topic of several research reports. Citigroup raised their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. UBS Group raised their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Morgan Stanley restated an “overweight” rating and set a $123.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. B. Riley Financial lifted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Finally, Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price target for the company.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, insider Noah Goodman sold 1,347 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $90.00, for a total value of $121,230.00. Following the completion of the sale, the insider owned 50,195 shares of the company’s stock, valued at $4,517,550. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 2,200 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $89.95, for a total value of $197,890.00. Following the completion of the sale, the director directly owned 4,159 shares of the company’s stock, valued at approximately $374,102.05. This represents a 34.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 344,434 shares of company stock worth $29,191,730. 16.01% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. Baker BROS. Advisors LP grew its holdings in shares of Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. lifted its position in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP bought a new stake in Kymera Therapeutics in the third quarter valued at approximately $47,563,000.

Kymera Therapeutics Stock Down 0.9%

Kymera Therapeutics stock opened at $86.93 on Friday. Kymera Therapeutics has a 52 week low of $25.50 and a 52 week high of $103.00. The business has a 50-day simple moving average of $84.21 and a 200 day simple moving average of $74.92. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of -23.62 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) earnings per share. On average, research analysts anticipate that Kymera Therapeutics will post -3.65 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.